Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Receivables - Other: 2017-2022

Historic Receivables - Other for Denali Therapeutics (DNLI) over the last 1 years, with Jun 2022 value amounting to $357,000.

  • Denali Therapeutics' Receivables - Other fell 77.22% to $357,000 in Q2 2022 from the same period last year, while for Jun 2022 it was $357,000, marking a year-over-year decrease of 77.22%. This contributed to the annual value of $1.2 million for FY2021, which is 78.39% down from last year.
  • According to the latest figures from Q2 2022, Denali Therapeutics' Receivables - Other is $357,000, which was down 70.88% from $1.2 million recorded in Q4 2021.
  • In the past 5 years, Denali Therapeutics' Receivables - Other registered a high of $5.7 million during Q4 2020, and its lowest value of $357,000 during Q2 2022.
  • Over the past 3 years, Denali Therapeutics' median Receivables - Other value was $1.4 million (recorded in 2021), while the average stood at $2.1 million.
  • As far as peak fluctuations go, Denali Therapeutics' Receivables - Other soared by 154.74% in 2018, and later slumped by 78.39% in 2021.
  • Quarterly analysis of 4 years shows Denali Therapeutics' Receivables - Other stood at $1.2 million in 2018, then reached $5.7 million in 2020, then slumped by 78.39% to $1.2 million in 2021, then plummeted by 77.22% to $357,000 in 2022.
  • Its Receivables - Other was $357,000 in Q2 2022, compared to $1.2 million in Q4 2021 and $1.2 million in Q3 2021.